In last trading session, Standard BioTools Inc (NASDAQ:LAB) saw 2.24 million shares changing hands with its beta currently measuring 1.56. Company’s recent per share price level of $1.35 trading at -$0.04 or -2.88% at ring of the bell on the day assigns it a market valuation of $502.55M. That closing price of LAB’s stock is at a discount of -125.19% from its 52-week high price of $3.04 and is indicating a premium of 13.33% from its 52-week low price of $1.17.

For Standard BioTools Inc (LAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Standard BioTools Inc (NASDAQ:LAB) trade information

Upright in the red during last session for losing -2.88%, in the last five days LAB remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.35 price level, adding 10.6% to its value on the day. Standard BioTools Inc’s shares saw a change of -22.86% in year-to-date performance and have moved -0.37% in past 5-day. Standard BioTools Inc (NASDAQ:LAB) showed a performance of -28.19% in past 30-days.

Wall Street analysts have assigned a consensus price target of 3.25 to the stock, which implies a rise of 58.46% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.25. It follows that stock’s current price would drop -140.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -140.74% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.72% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 62.06% while estimates for its earnings growth in next 5 years are of 56.66%.

Standard BioTools Inc (NASDAQ:LAB)’s Major holders

CASDIN CAPITAL, LLC is the top institutional holder at LAB for having 63.96 million shares of worth $113.21 million. And as of 2024-06-30, it was holding 17.1782 of the company’s outstanding shares.

The second largest institutional holder is VIKING GLOBAL INVESTORS LP, which was holding about 58.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7524 of outstanding shares, having a total worth of $103.81 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 9.27 shares of worth $12.51 million or 2.49% of the total outstanding shares. The later fund manager was in possession of 8.21 shares on Nov 30, 2024 , making its stake of worth around $11.08 million in the company or a holder of 2.21% of company’s stock.